Gainesville, FLNCT07759154Now EnrollingIRB Ready

Attention-deficit/Hyperactivity Disorder Clinical Trial in Gainesville, FL

Access cutting-edge attention-deficit/hyperactivity disorder treatment through this phase 3 clinical trial at a research site in Gainesville. Study-provided care at no cost to qualified participants.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.

Quick Self-Assessment

See if you qualify for this Gainesville location

Preparing your pre-screening questions…

Expert Care in Gainesville

Access attention-deficit/hyperactivity disorder specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related attention-deficit/hyperactivity disorder treatment provided free

Apply for This Gainesville Location

Check if you qualify for this attention-deficit/hyperactivity disorder clinical trial in Gainesville, FL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Gainesville

    Convenient for FL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Gainesville site if eligible
  4. 4Begin participation

About This Attention-deficit/Hyperactivity Disorder Study in Gainesville

The primary purpose of this study is to evaluate the efficacy of centanafadine once daily (QD) extended-release (XR) capsules in adults with attention-deficit/hyperactivity disorder (ADHD) and emotional dysregulation (ED).

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Who Can Participate

Inclusion Criteria

Primary diagnosis of ADHD per the Adult ADHD Clinical Diagnostic Scale (ACDS).
Adult ADHD Investigator Symptom Rating Scale (AISRS) total score of ≥ 28 at baseline.
Symptoms of ED as determined by the WRAADDS-ED subscale score ≥ 7 at baseline.
CGI-S-ADHD rating ≥ 4 (at least moderate severity) at baseline.

Exclusion Criteria

Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for a lifetime diagnosis of bipolar and related disorders, schizophrenia spectrum and other psychotic disorders, borderline and antisocial personality disorders, neurocognitive disorders, autism spectrum disorder, or intellectual disability.
DSM-5 criteria for a current diagnosis of major depressive disorder, post-traumatic stress disorder, any substance use disorder, untreated/unstable obstructive sleep apnea, eating disorders, or obsessive compulsive disorder.
Any other current DSM-5 comorbid psychiatric disorder identified by the Mini International Neuropsychiatric Interview (MINI) or any medical condition that, in the judgment of the investigator, could be expected to require treatment with medications prohibited in this trial that cannot be safely discontinued with completion of an appropriate washout, could confound efficacy or safety assessments, or be the primary driver of ED.
Presence of an unstable or uncontrolled medical condition that, in the opinion of the investigator, could pose a safety risk to the participant or could manifest with psychiatric symptoms (eg, thyroid disease).
In the clinical opinion of the investigator, the participant has not derived significant therapeutic benefit from 2 or more ADHD therapies of 2 different classes (eg, amphetamine and methylphenidate, or amphetamine and atomoxetine) given with an acceptable dose and duration during adulthood (aged 18 years or older).
Current use of prohibited psychotropic medications that cannot be discontinued within 7 to 28 days prior to enrollment.
Any disorder that is the primary focus of treatment other than ADHD.
Evidence of current substance use disorder or history in the past 12 months.
History of any prior exposure to centanafadine.
Participated in other clinical trials involving investigational drugs within 180 days prior to screening or participated in more than 2 interventional clinical trials involving investigational drugs within the past year.
Have an allergy to the IMP or any component of the IMP. Note: Other protocol-specified inclusion/exclusion criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Gainesville?

Yes, this clinical trial (NCT07759154) has an active research site in Gainesville, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Attention-deficit/Hyperactivity Disorder Treatment Options in Gainesville, FL

If you're searching for attention-deficit/hyperactivity disorder treatment options in Gainesville, FL, this clinical trial (NCT07759154) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Gainesville research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced attention-deficit/hyperactivity disorder specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all attention-deficit/hyperactivity disorder clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Embolism Trials in Gainesville, FL

See all pulmonary embolism clinical trials recruiting in Gainesville — not just this study.

Browse Pulmonary Embolism Trials in Gainesville →

Browse More Trials by Condition

Pulmonary Embolism TrialsADHD TrialsRheumatoid Arthritis TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Gainesville?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Gainesville, FL